Anales de la RANM

153 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 EVOLUCIÓN DE LA INSUFICIENCIA TRICÚSPIDE Arteagoitia Bolumburu A An RANM. 2024;141(02): 146 - 154 Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Car- diovasc Imaging. 2019; 12(3): 433-442. 5. Offen S, Playford D, Strange G, Stewart S, Ce- lermajer DS. Adverse prognostic impact of even mild or moderate tricuspid regurgitation: Insights from the national echocardiography database of Australia. J Am Soc Echocardiog. 2022; 35(8): 810-817. 6. Hahn RT, Lawlor MK, Davidson CJ et al. Tri- cuspid Valve Academic Research Consortium definitions for tricuspid regurgitation and trial endpoints. Eur Heart J. 2023; 44(43): 4508- 4532. 7. Hahn RT, Zamorano JL. The need for a new tri- cuspid regurgitation grading scheme. Eur Heart J-Card Img. 2017; 18(12): 1342-1343. 8. Fortuni F, Dietz MF, Prihadi EA et al. Prognos- tic implications of a novel algorithm to grade secondary tricuspid regurgitation. JACC Car- diovasc Imaging. 2021; 14(6):1085-1095. 9. Hahn RT. Tricuspid regurgitation. N Engl J Med. 2023; 388(20): 1876-1891. 10. Otto C, Nishimura R, Bonow RO et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: Executive summary: a report of the American College of Cardiology, American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021; 77(4): 450-500. 11. Konstam MA, Kiernan MS, Bernstein D et al. Evaluation and management of right-si- ded heart failure: a scientific statement from the American Heart Association. Circula- tion. 2018; 137(20): e578-e622. doi: 10.1161/ CIR.0000000000000560. 12. Maisano F, Hahn R, Sorajja P, Praz F, Lurz P. Transcatheter treatment of the tricuspid valve: Current status and perspectives. Eur Heart J. 2024; 45(11): 876-894. 13. Gavazzoni M, Heilbron F, Badano LP et al. The atrial secondary tricuspid regurgitation is as- sociated to more favorable outcome than the ventricular phenotype. Front Cardiovasc Med. 2022; 9: 1022755. 14. Prihadi EA, van der Bijl P, Gursoy E et al. Development of significant tricuspid regur- gitation over time and prognostic implica- tions: New insights into natural history. Eur Heart J. 2018; 39(39): 3574-3581. 15. Mutlak D, Khalil J, Lessick J, Kehat I, Agmon Y, Aronson D. Risk factors for the develo- pment of functional tricuspid regurgitation and their population-attributable fractions. JACC Cardiovasc Imaging. 2020; 13(8): 1643-1651. 16. Bannehr M, Edlinger CR, Kahn U et al. Na- tural course of tricuspid regurgitation and prognostic implications. Open Heart. 2021; 8(1): e001529. 17. Arteagoitia Bolumburu A, Monteagudo Ruiz JM, Mahia P et al. Determinants of tricuspid regurgitation progression and its implica- tions for adequate management. JACC Car- diovasc Imaging. 2024; 17(6): 579-591. doi: 10.1016/j.jcmg.2023.10.006. 18. Medvedofsky D, Aronson D, Gomberg- Maitland M et al. Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: Implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. Eur Heart J Cardiovasc Imaging. 2017; 18(1): 86-94. 19. Park JH, Shin SH, Lee MJ et al. Clinical and echocardiographic factors affecting tricus- pid regurgitation severity in the patients with lone atrial fibrillation. J Cardiovasc Ul- trasound. 2015; 23(3): 136. 20. Shiran A, Najjar R, Adawi S, Aronson D. Risk factors for progression of functional tricuspid regurgitation. Am J Cardiol. 2014; 113(6): 995-1000. 21. Bombace S, Fortuni F, Viggiani G et al. Right heart remodeling and outcomes in patients with tricuspid regurgitation: a literature review and meta-analysis. JACC Cardio- vasc Imaging. 2024 ;17(6): 595-606. doi: 10.1016/j.jcmg.2023.12.011. 22. Davidson LJ, Tang GHL, Ho EC et al. The tri- cuspid valve: a review of pathology, imaging, and current treatment options: a scientific statement from the American Heart Asso- ciation. Circulation. 2024; 149(22): e1223- e1238. doi: 10.1161/CIR.0000000000001232. 23. Dietz MF, Prihadi EA, Van Der Bijl P, Ajmo- ne Marsan N, Delgado V, Bax JJ. Prognostic implications of staging right heart failure in patients with significant secondary tricuspid regurgitation. JACC-Heart Fail. 2020; 8(8): 627-636. 24. Saeed S, Smith J, Grigoryan K, Urheim S, Chambers JB, Rajani R. Impact of pulmonary hypertension on outcome in patients with moderate or severe tricuspid regurgitation. Open Heart. 2019; 6(2): e001104. 25. Chen L, Larsen CM, Le RJ et al. The prog- nostic significance of tricuspid valve regur- gitation in pulmonary arterial hypertension. Clin Respir J. 2018; 12(4): 1572-1580. 26. Fortuni F, Butcher SC, Dietz MF et al. Right ventricular–pulmonary arterial coupling in secondary tricuspid regurgitation. Am J Car- diol. 2021; 148: 138-145. 27. Humbert M, Kovacs G, Hoeper MM et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38): 3618-3731. 28. Baratto C, Caravita S, Corbetta G et al. Im- pact of severe secondary tricuspid regurgi- tation on rest and exercise hemodynamics of patients with heart failure and a preserved left ventricular ejection fraction. Front Car- diovasc Med. 2023; 10: 1061118. 29. Harada T, Obokata M, Omote K et al. Functio- nal tricuspid regurgitation and right atrial re- modeling in heart failure with preserved ejec- tion fraction. Am J Cardiol. 2022; 162: 129-135. 30. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction. J Am Coll Cardiol. 2023; 81(18): 1810-1834. 31. Vahanian A, Beyersdorf F, Praz F et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022; 43(7): 561-632.